^
Association details:
| Biomarker: | AR positive |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer
Published date:
11/08/2021
Excerpt:
...to determine the safety and efficacy of the oral androgen receptor antagonist enzalutamide in patients with previously treated, recurrent, AR-positive (AR+) ovarian cancer. There was 1 confirmed and 1 unconfirmed partial response. The ORR was 1.7% (90% CI: 0.2-100%). The overall PFS6 rate (as binary) was 22% (90% CI: 15.1-100%). The 6-month PFS rate (as time to event) was 19.8% for HGS patients (90% CI: 12.7-100%) and 38.5% (90% CI: 21.7%-100%) for LGS patients. The study met its primary endpoint, with a PFS6 rate of 22% (n = 13)...
DOI:
10.1016/j.ygyno.2021.10.087
